HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway

Table 2 Univariate analysis of the correlation between clinicopathological variables and survival of patients with NSCLC

Clinicopathological variables	Median survival time (month)	Univariate analysis
Clinicopathological variables	Median survival time (month)	HR	95% CI	P value
Age		1.101	0.861–1.408	0.442
≥ 60	24.00 ± 2.931
< 60	34.00 ± 4.604
Sex		1.126	0.822–1.542	0.459
Female	34.00 ± 7.809
Male	27.00 ± 3.153
Smoking history		0.964	0.742–1.252	0.783
Never	30.00 ± 4.150
ever	27.00 ± 3.833
Maximal tumor size		1.583	1.221–2.052	0.001
< 5 cm	42.00 ± 5.431
≥ 5 cm	19.00 ± 2.255
T stage		1.986	1.534–2.570	< 0.001
T1-T2	49.00 ± 5.067
T3-T4	18.00 ± 1.874
Lymphatic invasion		1.662	1.293–2.135	< 0.001
N0	42.00 ± 6.041
N1-N3	23.00 ± 2.505
Distant metastasis		2.193	1.162–4.137	0.015
No	28.00 ± 3.102
Yes	11.00 ± 5.534
TNM stages		2.897	2.234–3.756	< 0.001
I-II	54.00 ± 5.189
III-IV	15.00 ± 1.786
Tumor differentiation		5.131	3.866–6.812	< 0.001
High and moderate	48.00 ± 3.288
poor	9.00 ± 1.333
Tumor HDAC7 expression		2.248	1.735–2.912	< 0.001
Low	41.00 ± 4.473
High	13.00 ± 2.220
Tumor FGF18 expression		2.029	1.578–2.608	< 0.001
Low	42.00 ± 4.321
High	15.00 ± 2.620

ISSN: 1756-9966